Values as of: 2024-10-30
COMMON STOCK | Medical Devices |
Last Closing
USD 51.34Change
-1.63 (-3.08)%Market Cap
USD 2.90BVolume
1.73MAnalyst Target
USD 65.00Verdict
Verdict
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Company Website : https://www.livanova.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| DXCM | DexCom Inc |
-0.44 (-0.61%) |
USD 29.04B |
| PODD | Insulet Corporation |
-1.79 (-0.77%) |
USD 16.66B |
| BRKR | Bruker Corporation |
+0.46 (+0.79%) |
USD 9.04B |
| MASI | Masimo Corporation |
+1.84 (+1.30%) |
USD 7.53B |
| TMDX | TransMedics Group Inc |
-6.58 (-7.44%) |
USD 4.17B |
| AXNX | Axonics Modulation Technologie.. |
+0.05 (+0.07%) |
USD 3.59B |
| PRCT | Procept Biorobotics Corp |
-3.66 (-3.79%) |
USD 3.50B |
| QDEL | Quidel Corporation |
+0.62 (+1.62%) |
USD 2.67B |
| NARI | Inari Medical Inc |
-2.08 (-4.23%) |
USD 2.57B |
| IRTC | iRhythm Technologies Inc |
-1.23 (-1.60%) |
USD 2.36B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| XHE | SPDR® S&P Health Care Eq.. | 2.00 % | 0.35 % |
+0.24 (+0.27%) |
USD 0.21B |
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -0.77% | 48% | F | 41% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -0.77% | 48% | F | 44% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 2.60% | 37% | F | 36% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 2.60% | 37% | F | 38% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -26.56% | 44% | F | 34% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -26.56% | 44% | F | 35% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 3.40% | 46% | F | 50% | F | ||
| Dividend Return | 3.40% | 46% | F | 46% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 36.31% | 75% | C | 51% | F | ||
| Risk Adjusted Return | 9.37% | 51% | F | 42% | F | ||
| Market Capitalization | 2.90B | 94% | A | 84% | B | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
